Clinical Scorecard: CGM in Early Gestational Diabetes Improved Outcomes
At a Glance
| Category | Detail |
|---|---|
| Condition | Gestational Diabetes |
| Key Mechanisms | Continuous glucose monitoring (CGM) vs self-monitoring of blood glucose. |
| Target Population | Patients diagnosed with gestational diabetes between 8 and 26 weeks’ gestation. |
| Care Setting | Single-center randomized controlled trial. |
Key Highlights
- CGM did not improve time in range but improved maternal and neonatal outcomes.
- Lower rates of preterm delivery (7% vs 18%) with CGM.
- Higher patient satisfaction with CGM (mean score 4.3/5).
- Fewer failed inductions leading to cesarean delivery (20% vs 44%) with CGM.
- CGM identified more hyperglycemic episodes than self-monitoring.
Guideline-Based Recommendations
Diagnosis
- Gestational diabetes diagnosed between 8 and 26 weeks’ gestation.
Management
- Consider CGM for improved maternal and neonatal outcomes despite no change in time in range.
Monitoring & Follow-up
- Monitor glucose levels continuously for better detection of glycemic excursions.
Risks
- Potential for underpowering of study and limitations due to single-center design.
Patient & Prescribing Data
128 patients enrolled, 120 completed the study.
CGM associated with better maternal and neonatal outcomes, including fewer NICU admissions.
Clinical Best Practices
- Utilize CGM for patients with gestational diabetes to enhance understanding of glucose levels.
- Monitor for hyperglycemic episodes more effectively with CGM.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
